CA
NZ
UK
AU
IND
US
Immunovant, Inc. has announced a net loss of $153.2 million for the fiscal first quarter ending June 30, 2026. This translates to a loss per share of $0.75, which is larger compared to the $0.71 loss reported in the same quarter last year. The …
This surge comes against a comparative anchor as Insmed reported an EPS of $-0.76 in the previous quarter, outperforming the consensus estimate of $-0.98. The dramatic revenue growth highlights the company’s operational success, especially as it navigates a competitive environment marked by live performances …
Intellia Therapeutics, Inc. (NASDAQ: NTLA) reported a second quarter EPS of $-0.80, slightly better than the consensus estimate of $-0.82. The company's performance reflects a determined approach in the gene-editing space, positioning itself for future growth. The results come amid fluctuations in share performance, …
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has reported exceptional quarterly results, achieving record revenues of around $99.3 million for the second quarter ending June 30, 2026. This revenue represents a significant 66% increase compared to approximately $60 million during the same period last year, as …
The company reported revenue of $113 million for the quarter ending June 30, which marks a significant increase from $85.2 million in the same period last year. However, the earnings per share (EPS) of $0.31 fell short of the $0.36 consensus estimate, which could …
The new trading environment will start on August 7, marking a key moment for the stock, which faces notable downward pressure this year.
Korro Bio, Inc. (NASDAQ: KRRO) has executed an exchange agreement with Venrock Healthcare Capital Partners to issue 1 million pre-funded warrants. This strategic move involves Venrock surrendering 1 million shares of Korro's common stock to the company at no cost, enhancing Korro's financial agility. …
The company's earnings per share (EPS) reached $0.02, surpassing the $-0.02 consensus estimate. This marks a significant performance uplift amid Evolent's efforts to deliver complex healthcare solutions, essential for investor confidence. The year-to-date revenue performance is a positive indicator of what lies ahead for …
Foghorn Therapeutics Inc. (NASDAQ: FHTX) posted a net loss of $7.2 million for the second quarter ended June 30, reflecting a significant improvement from the prior year's loss of $17.9 million. The company reported an earnings per share (EPS) of $-0.29, surpassing analyst expectations, …
The broader context shows that the company faced a challenging performance, particularly as it missed the consensus estimate for earnings per share (EPS), reporting a loss of $-1.06 against expectations of $-0.51. This drop in revenue highlights potential operational challenges that could deter investor …
Please wait processing your request...